Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Highlights ADA
Conference Highlights ADA
Look AHEAD Trial: Intensive Lifestyle Intervention Can Achieve Sustained Weight Loss in Type 2 Diabetes
Read More
Conference Highlights ADA
Anti-VEGF Antibody Injections Improve Vision in Diabetic Macular Edema
Read More
Conference Highlights ADA
Concern Raised About Ocular Risks of Diabetes Treatments
Read More
Conference Highlights ADA
Artificial Pancreas Passes Test in Patients with Type 1 Diabetes
Read More
Conference Highlights ADA
Intensive versus Standard Blood Pressure Control of No Benefit in Quality of Life for Patients with Type 2 Diabetes
Read More
Conference Highlights ADA
Medical Food Improves Symptoms of Diabetic Neuropathy
Read More
Conference Highlights ADA
HbA1c Screening Fails to Identify Many Patients with Diabetes and Prediabetes
Read More
Conference Highlights ADA
Education, Counseling Associated with Improved Clinical Outcomes in Type 2 Diabetes
Read More
Conference Highlights ADA
Ultra-Long-Acting Insulin Degludec Noninferior to Insulin Glargine with Less Hypoglycemia in Type 1 and Type 2 Diabetes
Read More
Conference Highlights ADA
Treatment Satisfaction Highest for Diabetic Patients Taking Only Oral Medications
Read More
1
2
3
Page 1 of 3
Results 1 - 10 of 22